Bristol-Myers Squibb (BMS) and Janssen Pharmaceuticals have entered a worldwide alliance to develop and commercialise a Factor XIa (FXIa) inhibitor, BMS-986177, to prevent and treat major thrombotic disorders.

The partners hope to establish a broad development programme for the FXIa inhibitor across various therapeutic indications.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the second half of this year, the companies intend to advance the investigational anticoagulant agent into Phase II clinical trials for secondary stroke prevention.

BMS executive vice-president and chief scientific officer Tom Lynch said: “We are proud to partner with Janssen on our shared vision for advancing cutting-edge science to develop potential new treatments such as BMS-986177 for serious cardiovascular disease.

“By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”

BMS-986177 is being developed to minimise the risk of vascular events without increasing the risk of bleeding in people with thrombotic conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”

These conditions include different cardiovascular disorders such as coronary artery disease, strokes and peripheral artery disease.

Janssen research & development global head Mathai Mammen said: “With the addition of a Factor XIa inhibitor programme to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide.

“With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterised by pathologic thrombosis.”

Janssen will make an undisclosed upfront payment to BMS, which is also eligible for additional milestone payments.

The partners are set to share development costs and commercial profits and losses.